Articles |

New Chemotherapeutic Agents for the Treatment of Non-small Cell Lung Cancer : The Japanese Experience FREE TO VIEW

Nagahiro Saijo
Author and Funding Information

From the Pharmacology Division and Medical Oncology Division, National Cancer Center Research Institute and Hospital, Tokyo, Japan

1998 by the American College of Chest Physicians

Chest. 1998;113(1_Supplement):17S-23S. doi:10.1378/chest.113.1_Supplement.17S
Text Size: A A A
Published online


Non-small cell lung cancer (NSCLC) is refractory to systemic chemotherapy, compared with small cell lung cancer. Until recently, only five drugs—cisplatin, vindesine, mitomyein, ifosfamide, and vinblastine—could produce overall response rates of 15% against NSCLC. However, recent efforts have contributed to the development of new drugs with activity against NSCLC, including irinotecan hydrochloride (CPT-11), paclitaxel, docetaxel, vinorelbine, and gemcitabine. Combination chemotherapy against NSCLC using these agents has demonstrated high response rates. In Japan, various combination chemotherapy and combined-modality regimens employing CPT-11 have been evaluated for their efficacy. Randomized controlled trials to establish new state-of-the-art treatments for NSCLC are ongoing.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543